How to identify pregnant women at risk of pre-eclampsia? - a review of the current literature

被引:3
作者
Kosinska-Kaczynska, Katarzyna [1 ]
Wielgos, Miroslaw [1 ]
机构
[1] Med Univ Warsaw, Dept Obstet & Gynecol 1, Starynkiewicza Sq 1-3, PL-02015 Warsaw, Poland
关键词
pre-eclampsia; prediction; PlGF; sFlt-1; risk factors; GROWTH-FACTOR RATIO; SUSPECTED PREECLAMPSIA; TYROSINE KINASE-1; METAANALYSIS; HYPERTENSION; ASPIRIN; PRETERM;
D O I
10.5603/GP.a2018.0057
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Pre-eclampsia remains a major cause of poor perinatal outcome worldwide. As administering acetylsalicylic acid in a high risk population reduces the risk of PE, it is essential to identify women at risk of PE. Several algorithms for PE risk assessment have been developed. They include maternal factors combined with uterine artery pulsatility index, mean arterial pressure, serum pregnancy-associated plasma protein-A, placental growth factor, and serum soluble fms-like tyrosine kinase-1. Beside PE prophylaxis with acetylsalicylic acid, a proper management of women considered at a high risk of PE is essential. The sFlt-1:PlGF ratio between 20 and 34 + 6 weeks may be used to predict a short-term absence of PE or to predict the risk of PE diagnosis within 4 weeks and a significant shortening of the duration of pregnancy associated with it. The sFlt-1:PlGF ratio may be helpful in deciding about hospitalization or choosing the optimal time for corticosteroid administration in women at risk of PE. It may also help to reduce overall healthcare costs.
引用
收藏
页码:335 / 338
页数:4
相关论文
共 24 条
  • [1] Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study
    Agrawal, Swati
    Cerdeira, Ana Sofia
    Redman, Christopher
    Vatish, Manu
    [J]. HYPERTENSION, 2018, 71 (02) : 306 - 316
  • [2] Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis
    Ananth, Cande V.
    Keyes, Katherine M.
    Wapner, Ronald J.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2013, 347
  • [3] Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation
    Andrietti, S.
    Silva, M.
    Wright, A.
    Wright, D.
    Nicolaides, K. H.
    [J]. ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2016, 48 (01) : 72 - 79
  • [4] Ba Sabria, 2018, ULTRASOUND OBST GYN, DOI [10.1002/uog.19040, DOI 10.1002/U0G.19040]
  • [5] Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia
    Frusca, Tiziana
    Gervasi, Maria-Teresa
    Paolini, Davide
    Dionisi, Matteo
    Ferre, Francesca
    Cetin, Irene
    [J]. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2017, 30 (18) : 2166 - 2173
  • [6] Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation
    Gallo, Dahiana M.
    Wright, David
    Casanova, Cristina
    Campanero, Mercedes
    Nicolaides, Kypros H.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (05) : 619.e1 - 619.e17
  • [7] The practical use of acetylsalicylic acid in the era of the ASPRE trial. Update and literature review
    Kosinski, Przemyslaw
    Sarzynska-Nowacka, Urszula
    Fiolna, Magdalena
    Wielgos, Miroslaw
    [J]. GINEKOLOGIA POLSKA, 2018, 89 (02) : 107 - 111
  • [8] The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application
    Lapaire, Olav
    Shennan, Andrew
    Stepan, Holger
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2010, 151 (02) : 122 - 129
  • [9] Soluble endoglin and other circulating antiangiogenic factors in preeclampsia
    Levine, Richard J.
    Lam, Chun
    Qian, Cong
    Yu, Kai F.
    Maynard, Sharon E.
    Sachs, Benjamin P.
    Sibai, Baha M.
    Epstein, Franklin H.
    Romero, Roberto
    Thadhani, Ravi
    Karumanchi, S. Ananth
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (10) : 992 - 1005
  • [10] Circulating angiogenic factors and the risk of preeclampsia
    Levine, RJ
    Maynard, SE
    Qian, C
    Lim, KH
    England, LJ
    Yu, KF
    Schisterman, EF
    Thadhani, R
    Sachs, BP
    Epstein, FH
    Sibai, BM
    Sukhatme, VP
    Karumanchi, SA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (07) : 672 - 683